Download PDF
Hamostaseologie 2022; 42(01): 010-018
DOI: 10.1055/a-1669-3336
Review Article

Treatment of Atypical Clots

Walter Ageno
1   Department of Medicine and Surgery, University of Insubria, Varese, Italy
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

The term unusual site thrombosis refers to the occurrence of venous thromboembolism outside of the lower limbs and the pulmonary arteries. Unusual site thrombosis can virtually affect any venous segment, with the most common and/or clinically relevant sites including the upper limbs veins, the retinal veins, the splanchnic veins and the cerebral veins. Clinical features are obviously heterogeneous, while many predisposing factors are common, though with different prevalence among the various disorders. Antithrombotic therapy is prescribed to most patients, but the type, intensity, and duration of treatment vary both within and among patient groups. Increasing evidence is supporting the use of the direct oral anticoagulants in patients with upper limb deep vein thrombosis, cerebral vein thrombosis, and with splanchnic vein thrombosis. This article will review available evidence on the treatment of venous thrombosis occurring in unusual sites.

Keywords

venous thrombosis - unusual site thrombosis - anticoagulation - direct oral anticoagulants


Publication History

Received: 21 August 2021

Accepted: 12 October 2021

Article published online:
23 February 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Lindblad B, Sternby NH, Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ 1991; 302 (6778): 709-711
    CrossrefPubMedGoogle Scholar
  • 2 Ageno W, Haas S, Weitz JI. et al. Upper extremity DVT versus lower extremity DVT: perspectives from the GARFIELD-VTE registry. Thromb Haemost 2019; 119 (08) 1365-1372
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Arnhjort T, Persson LM, Rosfors S, Ludwigs U, Lärfars G. Primary deep vein thrombosis in the upper limb: a retrospective study with emphasis on pathogenesis and late sequelae. Eur J Intern Med 2007; 18 (04) 304-308
    CrossrefPubMedGoogle Scholar
  • 4 Levy MM, Bach C, Fisher-Snowden R, Pfeifer JD. Upper extremity deep venous thrombosis: reassessing the risk for subsequent pulmonary embolism. Ann Vasc Surg 2011; 25 (04) 442-447
    CrossrefPubMedGoogle Scholar
  • 5 Tadlock MD, Chouliaras K, Kennedy M. et al. The origin of fatal pulmonary emboli: a postmortem analysis of 500 deaths from pulmonary embolism in trauma, surgical, and medical patients. Am J Surg 2015; 209 (06) 959-968
    CrossrefPubMedGoogle Scholar
  • 6 Newton DH, Monreal Bosch M, Amendola M. et al; RIETE Investigators. Analysis of noncatheter-associated upper extremity deep venous thrombosis from the RIETE registry. J Vasc Surg Venous Lymphat Disord 2017; 5 (01) 18.e1-24.e1
    PubMedGoogle Scholar
  • 7 Houghton DE, Casanegra AI, Peterson LG. et al. Treatment of upper extremity deep vein thrombosis with apixaban and rivaroxaban. Am J Hematol 2020; 95 (07) 817-823
    CrossrefPubMedGoogle Scholar
  • 8 Beiswenger AC, Quereshy HA, Rouabhi M. et al. Midterm outcomes in patients with upper extremity deep vein thrombosis. J Vasc Surg Venous Lymphat Disord 2020; 8 (06) 930.e2-938.e2
    PubMedGoogle Scholar
  • 9 Bleker SM, van Es N, Kleinjan A. et al. Current management strategies and long-term clinical outcomes of upper extremity venous thrombosis. J Thromb Haemost 2016; 14 (05) 973-981
    CrossrefPubMedGoogle Scholar
  • 10 Delluc A, Le Gal G, Scarvelis D, Carrier M. Outcome of central venous catheter associated upper extremity deep vein thrombosis in cancer patients. Thromb Res 2015; 135 (02) 298-302
    CrossrefPubMedGoogle Scholar
  • 11 Fan F, Zou Y, Zhang S. et al. Rivaroxaban in the treatment of PICC-associated upper extremity venous thrombosis. Clin Ther 2017; 39 (09) 1882-1888
    CrossrefPubMedGoogle Scholar
  • 12 Laube ES, Mantha S, Samedy P, Wills J, Harnicar S, Soff GA. Treatment of central venous catheter-associated deep venous thrombosis in cancer patients with rivaroxaban. Am J Hematol 2017; 92 (01) E9-E10
    CrossrefPubMedGoogle Scholar
  • 13 Kovacs MJ, Kahn SR, Rodger M. et al. A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study). J Thromb Haemost 2007; 5 (08) 1650-1653
    CrossrefPubMedGoogle Scholar
  • 14 Davies GA, Lazo-Langner A, Gandara E. et al. A prospective study of rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2). Thromb Res 2018; 162: 88-92
    CrossrefPubMedGoogle Scholar
  • 15 Rathbun SW, Stoner JA, Whitsett TL. Treatment of upper-extremity deep vein thrombosis. J Thromb Haemost 2011; 9 (10) 1924-1930
    CrossrefPubMedGoogle Scholar
  • 16 Porfidia A, Agostini F, Giarretta I. et al. Upper extremity deep vein thrombosis treated with direct oral anticoagulants: a multi-center real world experience. J Thromb Thrombolysis 2020; 50 (02) 355-360
    CrossrefPubMedGoogle Scholar
  • 17 Frank DA, Meuse J, Hirsch D, Ibrahim JG, van den Abbeele AD. The treatment and outcome of cancer patients with thromboses on central venous catheters. J Thromb Thrombolysis 2000; 10 (03) 271-275
    CrossrefPubMedGoogle Scholar
  • 18 Prandoni P, Bernardi E, Marchiori A. et al. The long term clinical course of acute deep vein thrombosis of the arm: prospective cohort study. BMJ 2004; 329 (7464): 484-485
    CrossrefPubMedGoogle Scholar
  • 19 Kearon C, Akl EA, Ornelas J. et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149 (02) 315-352
    CrossrefPubMedGoogle Scholar
  • 20 Kahn SR, Galanaud JP, Vedantham S, Ginsberg JS. Guidance for the prevention and treatment of the post-thrombotic syndrome. J Thromb Thrombolysis 2016; 41 (01) 144-153
    CrossrefPubMedGoogle Scholar
  • 21 Ageno W, Riva N, Schulman S. et al; IRSVT study group. Antithrombotic treatment of splanchnic vein thrombosis: results of an international registry. Semin Thromb Hemost 2014; 40 (01) 99-105
    PubMedGoogle Scholar
  • 22 Ageno W, Riva N, Schulman S. et al. Long-term clinical outcomes of splanchnic vein thrombosis: results of an international registry. JAMA Intern Med 2015; 175 (09) 1474-1480
    CrossrefPubMedGoogle Scholar
  • 23 Delgado MG, Seijo S, Yepes I. et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol 2012; 10 (07) 776-783
    CrossrefPubMedGoogle Scholar
  • 24 Turnes J, García-Pagán JC, González M. et al. Portal hypertension-related complications after acute portal vein thrombosis: impact of early anticoagulation. Clin Gastroenterol Hepatol 2008; 6 (12) 1412-1417
    CrossrefPubMedGoogle Scholar
  • 25 Di Nisio M, Valeriani E, Riva N, Schulman S, Beyer-Westendorf J, Ageno W. Anticoagulant therapy for splanchnic vein thrombosis: ISTH SSC Subcommittee Control of Anticoagulation. J Thromb Haemost 2020; 18 (07) 1562-1568
    CrossrefPubMedGoogle Scholar
  • 26 Riva N, Ageno W. Direct oral anticoagulants for unusual-site venous thromboembolism. Res Pract Thromb Haemost 2021; 5 (02) 265-277
    CrossrefPubMedGoogle Scholar
  • 27 Simonetto DA, Singal AK, Garcia-Tsao G, Caldwell SH, Ahn J, Kamath PS. ACG clinical guideline: disorders of the hepatic and mesenteric circulation. Am J Gastroenterol 2020; 115 (01) 18-40
    CrossrefPubMedGoogle Scholar
  • 28 Northup PG, Garcia-Pagan JC, Garcia-Tsao G. et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2021; 73 (01) 366-413
    CrossrefPubMedGoogle Scholar
  • 29 Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 (2, Suppl): e24S-e43S
    CrossrefPubMedGoogle Scholar
  • 30 Kearon C, Akl EA, Comerota AJ. et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 (2, Suppl): e419S-e496S
    CrossrefPubMedGoogle Scholar
  • 31 Key NS, Khorana AA, Kuderer NM. et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 2020; 38 (05) 496-520
    CrossrefPubMedGoogle Scholar
  • 32 Cohen O, Caiano LM, Tufano A, Ageno W. Cancer-associated splanchnic vein thrombosis. Semin Thromb Hemost 2021; 47 (08) 931-941
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Tufano A, Ageno W, Di Micco P. et al; RIETE Investigators. Outcomes during anticoagulation in patients with symptomatic vs. incidental splanchnic vein thrombosis. Thromb Res 2018; 164: 69-74
    CrossrefPubMedGoogle Scholar
  • 34 Cheng Q, Tree K. Systematic review of thrombolysis therapy in the management of non-cirrhosis-related portal vein thrombosis. J Gastrointest Surg 2021; 25 (06) 1579-1590
    CrossrefPubMedGoogle Scholar
  • 35 DeLeve LD, Valla DC, Garcia-Tsao G. American Association for the Study Liver Diseases. Vascular disorders of the liver. Hepatology 2009; 49 (05) 1729-1764
    CrossrefPubMedGoogle Scholar
  • 36 Cohen O, Pegoraro S, Ageno W. Cerebral venous thrombosis. Minerva Med 2021; . ( e-pub ahead of print) DOI: 10.23736/S0026-4806.21.07353-5.
    CrossrefPubMedGoogle Scholar
  • 37 Bousser MG, Ferro JM. Cerebral venous thrombosis: an update. Lancet Neurol 2007; 6 (02) 162-170
    CrossrefPubMedGoogle Scholar
  • 38 Ferro JM, Bousser MG, Canhão P. et al; European Stroke Organization. European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis - endorsed by the European Academy of Neurology. Eur J Neurol 2017; 24 (10) 1203-1213
    CrossrefPubMedGoogle Scholar
  • 39 Coutinho JM, Ferro JM, Zuurbier SM. et al. Thrombolysis or anticoagulation for cerebral venous thrombosis: rationale and design of the TO-ACT trial. Int J Stroke 2013; 8 (02) 135-140
    CrossrefPubMedGoogle Scholar
  • 40 Saposnik G, Barinagarrementeria F, Brown Jr RD. et al; American Heart Association Stroke Council and the Council on Epidemiology and Prevention. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42 (04) 1158-1192
    CrossrefPubMedGoogle Scholar
  • 41 Ferro JM, Coutinho JM, Dentali F. et al; RE-SPECT CVT Study Group. Safety and efficacy of dabigatran etexilate vs dose-adjusted warfarin in patients with cerebral venous thrombosis: a randomized clinical trial. JAMA Neurol 2019; 76 (12) 1457-1465
    CrossrefPubMedGoogle Scholar
  • 42 Miranda B, Aaron S, Arauz A. et al. The benefit of EXtending oral antiCOAgulation treatment (EXCOA) after acute cerebral vein thrombosis (CVT): EXCOA-CVT cluster randomized trial protocol. Int J Stroke 2018; 13 (07) 771-774
    CrossrefPubMedGoogle Scholar
  • 43 Hayreh SS, Zimmerman MB, Beri M, Podhajsky P. Intraocular pressure abnormalities associated with central and hemicentral retinal vein occlusion. Ophthalmology 2004; 111 (01) 133-141
    CrossrefPubMedGoogle Scholar
  • 44 Raslan OM, Lazo-Langner A. Treatment of retinal vein thrombosis: what about anticoagulants?. Minerva Med 2021; . ( e-pub ahead of print) DOI: 10.23736/S0026-4806.21.07474-7.
    CrossrefPubMedGoogle Scholar
  • 45 Pulido JS, Flaxel CJ, Adelman RA, Hyman L, Folk JC, Olsen TW. Retinal vein occlusions preferred practice Pattern(®) guidelines. Ophthalmology 2016; 123 (01) 182-208
    CrossrefPubMedGoogle Scholar
  • 46 Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS. et al. Guidelines for the management of retinal vein occlusion by the European Society of Retina Specialists (EURETINA). Ophthalmologica 2019; 242 (03) 123-162
    CrossrefPubMedGoogle Scholar
  • 47 Ageno W, Beyer-Westendorf J, Garcia DA, Lazo-Langner A, McBane RD, Paciaroni M. Guidance for the management of venous thrombosis in unusual sites. J Thromb Thrombolysis 2016; 41 (01) 129-143
    CrossrefPubMedGoogle Scholar
  • 48 Lazo-Langner A, Hawel J, Ageno W, Kovacs MJ. Low molecular weight heparin for the treatment of retinal vein occlusion: a systematic review and meta-analysis of randomized trials. Haematologica 2010; 95 (09) 1587-1593
    CrossrefPubMedGoogle Scholar
  • 49 Belcaro G, Dugall M, Bradford HD. et al. Recurrent retinal vein thrombosis: prevention with Aspirin, Pycnogenol®, ticlopidine, or sulodexide. Minerva Cardioangiol 2019; 67 (02) 109-114
    CrossrefPubMedGoogle Scholar
  • 50 Rodriguez P, Belcaro G, Dugall M. et al. Recurrence of retinal vein thrombosis with Pycnogenol® or Aspirin® supplementation: a registry study. Panminerva Med 2015; 57 (03) 121-125
    PubMedGoogle Scholar
  • 51 Shi W, Dowell JD. Etiology and treatment of acute inferior vena cava thrombosis. Thromb Res 2017; 149: 9-16
    CrossrefPubMedGoogle Scholar
  • 52 Watson L, Broderick C, Armon MP. Thrombolysis for acute deep vein thrombosis. Cochrane Database Syst Rev 2016; 11: CD002783
    PubMedGoogle Scholar
  • 53 Vedantham S, Goldhaber SZ, Julian JA. et al; ATTRACT Trial Investigators. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N Engl J Med 2017; 377 (23) 2240-2252
    CrossrefPubMedGoogle Scholar
  • 54 Comerota AJ, Kearon C, Gu CS. et al; ATTRACT Trial Investigators. Endovascular thrombus removal for acute iliofemoral deep vein thrombosis. Circulation 2019; 139 (09) 1162-1173
    CrossrefPubMedGoogle Scholar
  • 55 Alkhouli M, Zack CJ, Zhao H, Shafi I, Bashir R. Comparative outcomes of catheter-directed thrombolysis plus anticoagulation versus anticoagulation alone in the treatment of inferior vena caval thrombosis. Circ Cardiovasc Interv 2015; 8 (02) e001882
    CrossrefPubMedGoogle Scholar
  • 56 Asghar M, Ahmed K, Shah SS, Siddique MK, Dasgupta P, Khan MS. Renal vein thrombosis. Eur J Vasc Endovasc Surg 2007; 34 (02) 217-223
    CrossrefPubMedGoogle Scholar
  • 57 Kodali N, Veytsman I, Martyr S, Lu K. Diagnosis and management of ovarian vein thrombosis in a healthy individual: a case report and a literature review. J Thromb Haemost 2017; 15 (02) 242-245
    CrossrefPubMedGoogle Scholar
  • 58 Bannow BTS, Skeith L. Diagnosis and management of postpartum ovarian vein thrombosis. Hematology (Am Soc Hematol Educ Program) 2017; 2017 (01) 168-171
    CrossrefPubMedGoogle Scholar